FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283558> ?p ?o ?g. }

• W4379283558 endingPage "TPS2669" @default.
• W4379283558 startingPage "TPS2669" @default.
• W4379283558 abstract "TPS2669 Background: Claudin 6 (CLDN6), an oncofetal antigen that is expressed on the cell surface of several solid cancers, including testicular (95% of cases) and ovarian cancers (55% of cases), is a suitable target for cancer immunotherapy (Reinhard et al. Science. 2020; Haanen et al. AACR 2022). BNT142 comprises lipid nanoparticle-encapsulated RNAs that encode for a T-cell-engaging bispecific antibody against CLDN6 and the T cell receptor–associated molecule CD3. The resulting tribody is produced from two RNA molecules coding for CLDN6-recognizing single-chain variable fragments connected by a CD3-binding fragment antigen-binding region. After intravenous administration, BNT142 is directed to the liver where both RNAs are translated, assembled, and secreted as antibodies into the circulation. While classical recombinant protein antibody formats are affected by issues with stability and a lengthy manufacturing process, novel RNA-encoded antibodies can be developed quickly and will potentially provide more favorable exposure profiles. A previous preclinical study examining the therapeutic effect of RNA-encoded bispecific CLDN6xCD3 antibodies showed tumor regression in xenograft animal models with CLDN6+ tumors (Stadler et al. Nat Med. 2017). Methods: This is a first-in-human, Phase I/II, open-label, multicenter, dose escalation trial with expansion cohorts to evaluate the safety, efficacy, PK and PD of BNT142 in patients with CLDN6+ advanced solid tumors (NCT05262530). Patients with advanced/metastatic CLDN6+ testicular, ovarian, endometrial, and non-squamous non-small-cell lung cancer (NSCLC) are eligible for inclusion and are prospectively selected for trial entry using a CLDN6 immunohistochemistry assay in a central laboratory. Patients must have exhausted standard therapies available likely to confer a clinical benefit or not be a candidate for such available therapies. The trial design consists of a dose escalation and dose expansion part. In the dose escalation part, the treatment dose will be escalated in up to 8 dose levels (DLs) until the maximum administered and tolerated dose has been reached. Once a DL has been declared safe, the DL cohort may be backfilled to determine safety, PK/PD, and anti-tumor activity. Patients with rare or not otherwise specified CLDN6+ tumors not included in the eligible tumor types can be included in the dose escalation part. The recommended Phase II dose (RP2D) will be determined by data collected at all DLs. In the dose expansion part, CLDN6+ patients with testicular cancer, ovarian cancer, and non-squamous NSCLC who have received at least 1 systemic therapy will be treated at the RP2D. The trial was initiated in March 2022 and recruitment is ongoing at global locations in Europe and the USA. Additional sites will be opened in Europe, USA, and Asia in 2023. Clinical trial information: NCT05262530 ." @default.
• W4379283558 created "2023-06-05" @default.
• W4379283558 creator A5000036560 @default.
• W4379283558 creator A5001209967 @default.
• W4379283558 creator A5006683670 @default.
• W4379283558 creator A5013760636 @default.
• W4379283558 creator A5016786386 @default.
• W4379283558 creator A5022467575 @default.
• W4379283558 creator A5029650119 @default.
• W4379283558 creator A5033253306 @default.
• W4379283558 creator A5044493081 @default.
• W4379283558 creator A5044613951 @default.
• W4379283558 creator A5045951746 @default.
• W4379283558 creator A5059035314 @default.
• W4379283558 creator A5068368047 @default.
• W4379283558 creator A5075617216 @default.
• W4379283558 creator A5078475489 @default.
• W4379283558 creator A5083868231 @default.
• W4379283558 creator A5088040773 @default.
• W4379283558 creator A5089962252 @default.
• W4379283558 creator A5090211062 @default.
• W4379283558 creator A5092083780 @default.
• W4379283558 date "2023-06-01" @default.
• W4379283558 modified "2023-10-15" @default.
• W4379283558 title "A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors." @default.
• W4379283558 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.tps2669" @default.
• W4379283558 hasPublicationYear "2023" @default.
• W4379283558 type Work @default.
• W4379283558 citedByCount "1" @default.
• W4379283558 countsByYear W43792835582023 @default.
• W4379283558 crossrefType "journal-article" @default.
• W4379283558 hasAuthorship W4379283558A5000036560 @default.
• W4379283558 hasAuthorship W4379283558A5001209967 @default.
• W4379283558 hasAuthorship W4379283558A5006683670 @default.
• W4379283558 hasAuthorship W4379283558A5013760636 @default.
• W4379283558 hasAuthorship W4379283558A5016786386 @default.
• W4379283558 hasAuthorship W4379283558A5022467575 @default.
• W4379283558 hasAuthorship W4379283558A5029650119 @default.
• W4379283558 hasAuthorship W4379283558A5033253306 @default.
• W4379283558 hasAuthorship W4379283558A5044493081 @default.
• W4379283558 hasAuthorship W4379283558A5044613951 @default.
• W4379283558 hasAuthorship W4379283558A5045951746 @default.
• W4379283558 hasAuthorship W4379283558A5059035314 @default.
• W4379283558 hasAuthorship W4379283558A5068368047 @default.
• W4379283558 hasAuthorship W4379283558A5075617216 @default.
• W4379283558 hasAuthorship W4379283558A5078475489 @default.
• W4379283558 hasAuthorship W4379283558A5083868231 @default.
• W4379283558 hasAuthorship W4379283558A5088040773 @default.
• W4379283558 hasAuthorship W4379283558A5089962252 @default.
• W4379283558 hasAuthorship W4379283558A5090211062 @default.
• W4379283558 hasAuthorship W4379283558A5092083780 @default.
• W4379283558 hasConcept C114684123 @default.
• W4379283558 hasConcept C121608353 @default.
• W4379283558 hasConcept C126322002 @default.
• W4379283558 hasConcept C147483822 @default.
• W4379283558 hasConcept C159654299 @default.
• W4379283558 hasConcept C167672396 @default.
• W4379283558 hasConcept C203014093 @default.
• W4379283558 hasConcept C204232928 @default.
• W4379283558 hasConcept C2777701055 @default.
• W4379283558 hasConcept C502942594 @default.
• W4379283558 hasConcept C542903549 @default.
• W4379283558 hasConcept C71924100 @default.
• W4379283558 hasConceptScore W4379283558C114684123 @default.
• W4379283558 hasConceptScore W4379283558C121608353 @default.
• W4379283558 hasConceptScore W4379283558C126322002 @default.
• W4379283558 hasConceptScore W4379283558C147483822 @default.
• W4379283558 hasConceptScore W4379283558C159654299 @default.
• W4379283558 hasConceptScore W4379283558C167672396 @default.
• W4379283558 hasConceptScore W4379283558C203014093 @default.
• W4379283558 hasConceptScore W4379283558C204232928 @default.
• W4379283558 hasConceptScore W4379283558C2777701055 @default.
• W4379283558 hasConceptScore W4379283558C502942594 @default.
• W4379283558 hasConceptScore W4379283558C542903549 @default.
• W4379283558 hasConceptScore W4379283558C71924100 @default.
• W4379283558 hasIssue "16_suppl" @default.
• W4379283558 hasLocation W43792835581 @default.
• W4379283558 hasOpenAccess W4379283558 @default.
• W4379283558 hasPrimaryLocation W43792835581 @default.
• W4379283558 hasRelatedWork W1943797027 @default.
• W4379283558 hasRelatedWork W1997716688 @default.
• W4379283558 hasRelatedWork W2038126255 @default.
• W4379283558 hasRelatedWork W2064089409 @default.
• W4379283558 hasRelatedWork W2073282260 @default.
• W4379283558 hasRelatedWork W2074123101 @default.
• W4379283558 hasRelatedWork W2123042378 @default.
• W4379283558 hasRelatedWork W2413628880 @default.
• W4379283558 hasRelatedWork W227218597 @default.
• W4379283558 hasRelatedWork W45891745 @default.
• W4379283558 hasVolume "41" @default.
• W4379283558 isParatext "false" @default.
• W4379283558 isRetracted "false" @default.
• W4379283558 workType "article" @default.